Screener
Agios Pharmaceuticals AGIO Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's operating lease liability - undiscounted excess amount?
- Agios Pharmaceuticals (AGIO) reported operating lease liability - undiscounted excess amount of $1.5M in Q2 2026.
- How has Agios Pharmaceuticals's operating lease liability - undiscounted excess amount changed year-over-year?
- Agios Pharmaceuticals's operating lease liability - undiscounted excess amount decreased by 60.6% year-over-year, from $3.82M to $1.5M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.
Ask your AI about Agios Pharmaceuticals's operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude